Back to top
more

ICU Medical (ICUI)

(Delayed Data from NSDQ)

$129.02 USD

129.02
330,569

-1.04 (-0.80%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $128.97 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Pfizer (PFE) Q1 Earnings Beat, Sales Lag, 2017 View Intact

by Zacks Equity Research

Pfizer, Inc. (PFE) reported first-quarter 2017 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate of 67 cents by 3%.

    Zacks Equity Research

    MedTech Stocks' Q4 Earnings on Mar 1: ICUI, GKOS & EGRX

    by Zacks Equity Research

    Let's take a look at the major MedTech stocks within the broader medical community, slated to release their reports on Mar 1.

      Zacks Equity Research

      Walgreens Teams Up with Fedex to Boost Retail Performance

      by Zacks Equity Research

      Walgreens Boots Alliance, Inc. (WBA) recently inked a multi-year partnership agreement with global express delivery services company FedEx Corporation (FDX).

        Zacks Equity Research

        Align Poised On Global Expansion & Invisalign Teen Growth

        by Zacks Equity Research

        On Jan 10, 2017, we issued an updated research report on California-based Align Technology Inc. (ALGN).

          Zacks Equity Research

          Illumina (ILMN) Launches NovaSeq Series for $100 Genome

          by Zacks Equity Research

          Illumina, Inc. (ILMN) recently unveiled the NovaSeq Series, a scalable sequencing solution expected to enable a $100 genome.

            Zacks Equity Research

            QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite

            by Zacks Equity Research

            QIAGEN N.V. (QGEN) recently announced the acquisition of Cary, NC-based OmicSoft Corporation.

              Zacks Equity Research

              LLabCorp: Reimbursement Scenario a Drag Amid Other Woes

              by Zacks Equity Research

              On Jan 09, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH) or LabCorp.

                Zacks Equity Research

                ResMed and Dr. Oz Form SleepScore Labs for Sleep Disorders

                by Zacks Equity Research

                ResMed Inc. (RMD) recently formed a joint venture with renowned surgeon and television host Dr. Mehmet Oz and private equity firm Pegasus Capital Advisors, L.P.

                  Zacks Equity Research

                  Myriad Genetics: Evidence Street Reviews EndoPredict Test

                  by Zacks Equity Research

                  Myriad Genetics, Inc. (MYGN) recently announced that Blue Cross Blue Shield Association's technical assessment provider Evidence Street has reviewed its EndoPredict assay.

                    Zacks Equity Research

                    Walgreens Boots (WBA) Beats Q1 Earnings, Trims EPS View

                    by Zacks Equity Research

                    Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.10 in first-quarter fiscal 2017, up 6.8% from the year-ago quarter.

                      Zacks Equity Research

                      Bruker Buys InVivo Biotech, Boosts MALDI Biotyper Suite

                      by Zacks Equity Research

                      Bruker Corporation (BRKR) recently announced the buyout of Hennigsdorf, Germany-based InVivo Biotech Services GmbH.

                        Zacks Equity Research

                        Bruker Buys SCiLS, Expands in Mass Spectrometry Imaging

                        by Zacks Equity Research

                        Bruker Corporation (BRKR) recently announced the acquisition of Bremen, Germany-based software solutions developer, SCiLS GmbH.

                          Zacks Equity Research

                          ResMed Achieves Key Milestone in Sleep-Disordered Breathing

                          by Zacks Equity Research

                          After one billion nights of sleep data was downloaded using ResMed's remote patient monitoring platform AirView, the company reached a landmark in the field of sleep research and treatment of sleep apnea.

                            Zacks Equity Research

                            4 Medical Device Stocks on a Bull Run this Earnings Season

                            by Zacks Equity Research

                            The expected positive third-quarter performance by the broader Medical sector is something investors definitely need to muse on.